miscellaneous - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.56 [0.26, 1.21]< 10%7 studies (7/-)92.9 %some concernnot evaluable moderatecrucial-
death or transfer to ICU 0.55 [0.26, 1.17]< 10%1 study (1/-)93.9 %some concernnot evaluable moderatecrucial-
deaths 0.49 [0.22, 1.08]< 10%7 studies (7/-)96.2 %some concernnot evaluable moderatecrucial-
deaths (time to event analysis only) 0.35 [0.06, 1.96]< 152%2 studies (2/-)88.4 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.33 [0.03, 3.75]< 10%2 studies (2/-)81.2 %some concernnot evaluable moderateimportant-
clinical improvement 1.29 [0.99, 1.67]> 114%5 studies (5/-)97.2 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 10.27 [1.17, 90.18]> 10%1 study (1/-)98.2 %some concernnot evaluable moderateimportant-
clinical improvement (21-day) 2.09 [0.04, 119.96]> 10%1 study (1/-)63.7 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 2.98 [0.59, 15.15]> 10%3 studies (3/-)90.6 %some concernnot evaluable moderateimportant-
clinical improvement (7-day) 6.72 [1.50, 30.07]> 10%1 study (1/-)99.4 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.14 [0.83, 1.57]> 10%1 study (1/-)79.0 %some concernnot evaluable moderateimportant-
hospital discharge 10.00 [1.03, 97.50]> 10%1 study (1/-)97.5 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.52 [0.13, 2.13]< 138%5 studies (5/-)81.6 %some concernserious moderateimportant-
mechanical ventilation (time to event analysis only) 0.69 [0.14, 3.42]< 10%1 study (1/-)67.5 %some concernnot evaluable moderateimportant-
viral clearance by day 14 1.00 [0.03, 34.67]> 10%1 study (1/-)50.0 %some concernnot evaluable moderateimportant-
ICU admission 0.80 [0.34, 1.90]< 10%1 study (1/-)69.4 %some concernnot evaluable moderatenon important-
recovery 1.24 [0.69, 2.23]> 135%4 studies (4/-)76.3 %some concernnot evaluable moderatenon important-

safety endpoints 00

related AE (TRAE) 1.26 [0.14, 11.07]< 10%2 studies (2/-)41.9 %some concernnot evaluable moderateimportant-
serious adverse events 0.61 [0.08, 4.90]< 173%3 studies (3/-)67.9 %some concernnot evaluable moderateimportant-
adverse events 0.73 [0.44, 1.21]< 13%6 studies (6/-)89.2 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.